text: One possible treatment for cancer involves monoclonal antibodies that bind only to cancer-cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin, radioisotope, cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab regions both to target antigen and to a conjugate or effector cell. Every intact antibody can bind to cell receptors or other proteins with its Fc region.
   MAbs approved by the FDA for cancer include:
  * Alemtuzumab
  * Bevacizumab
  * Cetuximab
  * Dostarlimab
  * Gemtuzumab ozogamicin
  * Ipilimumab
  * Nivolumab
  * Ofatumumab
  * Panitumumab
  * Pembrolizumab
  * Ranibizumab
  * Rituximab
  * Trastuzumab